Human Host Cell Fusion for Stable EBV Genome Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human host cells used for producing recombinant proteins often lose Epstein-Barr virus (EBV) genomes during cultivation, leading to a loss of beneficial properties for effective expression of heterologous genes, particularly in cell lines like HKB cells.
Innovation Solution
A human host cell line is generated by fusing a human embryonic kidney-derived cell, such as a 293 cell, with a human B-cell-derived cell, like Namalwa, with the EBV genome integrated into its chromosomes, ensuring stable expression of EBNA1 and glycosylation profiles similar to humans, and lacking IgM expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If HKB cells are used for producing recombinant proteins, then transfection efficiency and protein secretion are improved, but EBV genome is lost during cultivation
Solution Approach 1:
The patent merges the EBV genome into the chromosomal DNA of the host cell rather than maintaining it as a separate episomal element. This integration ensures that the EBV genome is replicated and inherited stably during cell division, preventing the loss observed in traditional HKB cells while maintaining the beneficial properties for protein production
Solution Approach 2:
The EBV genome is integrated into the host cell chromosome before the establishment of the cell line for protein production. This preliminary integration action ensures that subsequent cell passages and cultivations will maintain stable EBV genome presence without requiring continuous selection pressure
2Manufacturing precision
If human embryonic kidney cells are used for protein production, then human-like glycosylation profiles are achieved, but aggregation occurs in serum-free suspension culture
Solution Approach 1:
The patent combines human embryonic kidney cells (providing human-like glycosylation) with B-cell-derived cells (providing suspension culture adaptability). This cell fusion creates a hybrid cell line that inherits the glycosylation capabilities of renal cells while gaining the suspension culture properties of B-cell lines, eliminating aggregation issues
3Productivity
If cell fusion is performed to combine beneficial properties, then transfection efficiency and protein secretion are improved, but cell line complexity increases
Solution Approach 1:
The patent extracts and integrates only the essential EBV genome into the host cell chromosome, removing the need for maintaining complex episomal structures or multiple plasmid systems. This extraction approach simplifies the overall cell line architecture while preserving the key functional benefits for protein production
Data Source
Figure 1
Figure 2A~3
Figure 4A~4B
AI summary
The present invention relates to a human host cell generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, by using genetic engineering techniques. The human host cell with stable characteristics well preserved may be efficiently used to produce heterologous desired recombinant protein-based pharmaceuticals.